Brainstorm Cell Therapeutics (NASDAQ:BCLI) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.12, MarketWatch Earnings reports.
Brainstorm Cell Therapeutics stock opened at $15.29 on Friday. The stock has a market capitalization of $482.68 million, a PE ratio of -13.18 and a beta of 0.83. Brainstorm Cell Therapeutics has a 12 month low of $3.58 and a 12 month high of $17.95. The business has a 50 day simple moving average of $14.59 and a 200-day simple moving average of $10.66.
Several brokerages recently weighed in on BCLI. Maxim Group lifted their price target on Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. BidaskClub upgraded Brainstorm Cell Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 30th.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Article: Beige Book
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.